Newly Formed Lanier Biotherapeutics Enters into License Agreement with Alloy Therapeutics
October 05, 2021 08:00 ET
|
Lanier Biotherapeutics
BOGART, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Lanier Biotherapeutics Inc., (“Lanier” or the “Company”), a developer of first-in-class antibodies targeting retina, dermatology, and Type 2...